ProQR Therapeutics down after $90 mln equity raise

ProQR Therapeutics NV

31/03/2021 11:32

** ProQR Therapeutics  PRQR.O  down ~6% on light premarket
volume after co prices follow-on - shares have fallen for past 3
sessions
    ** PRQR sells ~13.8 mln shares at $6.50, raises $90 mln
 urn:newsml:reuters.com:*:nGNX7QfMZZ
    ** Offering size increased from $80 mln, prices at 8.8%
discount to stock's last sale
    ** Citigroup and Evercore joint lead bookrunners
    ** Co has ~54.1 mln shares outstanding for ~$386 mln market
cap, per Refinitiv data, and ~48.6 mln of free float
    ** Early last Weds, co reported positive results from
early-to-mid stage study for its RNA therapy for Usher Syndrome,
rare cause of childhood-onset deafness and blindness. Last
Thurs, PRQR's stock surged 62% to $9.22  urn:newsml:reuters.com:*:nL4N2LM3U6
    ** All 7 analysts covering PRQR recommend buying the stock
with median PT of $22 (Refinitiv)

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper.tr.com@reuters.net
lance.tupper@tr.com 1-332-219-1430))